📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

The Vita Coco Company, Inc. develops, manufactures, markets, and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa, and the Asia Pacific. It offers coconut water, oil, and juice products; Vita Coco Treats, a plant-based dairy alternative; Vita Coco Pressed, Vita Coco Coconut Juice, and Farmers Organic; Vita Coco Coconut MLK; and PWR LIFT, a protein-infused fitness drink. The company also supplies private label products to retailers. It distributes its products through club, food, drug, mass, convenience, e-commerce, and foodservice channels. The company was formerly known as All Market Inc. and changed its name to The Vita Coco Company, Inc. in September 2021. The Vita Coco Company, Inc. was incorporated in 2004 and is headquartered in New York, New York.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management expressed strong confidence in top-line growth, citing specific metrics like 17% net sales growth and 25% Vita Coco Coconut Water growth. They provided detailed explanations for gross margin decline (450bps) and tariff assumptions, while also acknowledging uncertainties in ocean freight and tariff impacts.

Q3 2025

Confident Specific

Management repeatedly used phrases like 'strong performance', 'exceptionally strong results', and 'very high execution levels' while providing specific growth percentages and detailed tariff mitigation plans, indicating confidence backed by data.

Q4 2025

Confident Specific

Management repeatedly used language like 'record year', 'excellent full-year results', 'very healthy', and 'strong momentum'. They provided specific growth percentages (e.g., US category +22%, Vita Coco +26%, International +37%) and gave numeric guidance for 2026 (net sales $680-700M, gross margin ~38%, Adj. EBITDA $122-128M).

Q1 2026 latest

Confident Specific

Management repeatedly cited specific growth numbers (e.g., '40%' retail dollar growth for Vita Coco, '57%' international growth), quantified drivers (e.g., '3%' price impact, '5%' Walmart reset benefit), and raised full-year guidance with exact ranges. Language like 'thrilled,' 'excited,' 'very confident' shows strong conviction.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is stronger after this call. The coconut water category acceleration (US +31%, Europe +63%) and Vita Coco brand growth (+40% US retail dollars) exceeded expectations, leading to a raised full-year outlook. Management demonstrated solid cost control with gross margins expanding despite inflation. Key positive: the company is gaining share in both branded and private label, and international growth is becoming a significant driver. Risks to watch: H2 margin compression from Middle East-related inflation, whether the demand surge is sustainable, and execution on capacity expansion for 2027. However, with a strong balance sheet and no debt, Vita Coco is well-positioned to invest for long-term growth. Next quarter, focus on whether Q2 shipments confirm the acceleration and any updates on pricing actions if inflation continues.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Vita Coco Q1 2026 net sales $180M (+37% YoY), raises full-year guidance

Revenue & Profitability

Q1 2026 net sales were $180 million, up $49 million or 37% year-over-year. Gross profit was $72 million, with gross margin of 40% (up 320 bps from 37% in Q1 2025). Net income attributable to shareholders was $30 million or $0.50 per diluted share (vs. $19 million or $0.31 in Q1 2025). Adjusted EBITDA was $39 million or 22% of net sales (up from $23 million or 17% in Q1 2025).

Outlook

Management sees coconut water as one of the fastest-growing beverage categories, with U.S. retail dollar growth of 31% and European measured market growth of 63% in Q1 2026. They believe the category is in the early stages of gaining mainstream appeal globally. Key tailwinds include consumer demand for hydration and functional beverages. Headwinds include inflationary pressures from Middle East conflict and potential ocean freight costs.

Growth Drivers

Growth is driven by strong branded volume and household penetration gains in the U.S. and international markets. International growth, especially in Europe (U.K., Germany), is accelerating with 57% retail dollar growth in measured European markets. Private label is resurging, with expected 35-40% net sales growth in the U.S. in 2026. Expansion in convenience stores (C-store ACV grew from 55% to 59% on core items) and the Treats coconut milk platform also contribute.

Balance Sheet & CapEx

Management is expanding supply chain capacity for 2027 and beyond to meet expected continued growth. They plan to operate at 85%-90% of committed capacity in 2026 (vs. typical 80%-85%). Investments are being made in organizational capabilities, marketing, and the Singapore team to support capacity expansion. Specific CapEx guidance was not provided, but the company is prioritizing capacity investments over non-essential spending.

Margins

Gross margin improved to 40% in Q1 2026 from 37% a year ago, driven by better branded pricing and lower ocean freight, partially offset by inflation and tariffs. Full-year 2026 gross margin guidance is approximately 38%. Q2 margins are expected similar to Q1, with slight declines in H2 due to inflationary factors and planned promotions. SG&A is expected to increase high single digits as a percentage of net sales but deliver about one point of leverage over 2025.

Key Risks

Key risks include inflationary pressures from the Middle East conflict (affecting packaging, energy, and domestic logistics) and potential ocean freight cost increases. There is uncertainty regarding a $15.6 million tariff refund claim through the CBP CAPE portal. Capacity constraints could lead to service issues if demand surges beyond expectations. The company also faces foreign currency exposure and potential supply chain disruptions from fuel scarcity in sourcing countries.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-07-23

Q2 2026 saw net sales rise 28% year-over-year, with strong branded and private label growth, and gross margin up to 49%. The Copra acquisition expands presence in the super premium segment and is expected to be EBITDA accretive. Full-year guidance was raised for both net sales and adjusted EBITDA.

Q1 2026 Q1 2026 2026-04-29

Q1 2026 saw 37% net sales growth, margin expansion, and strong international momentum, prompting raised full-year guidance. Category acceleration is driven by hydration trends, younger consumers, and robust private label growth, with inflation and supply chain managed within outlook.

Q4 2025 Q4 2025 2026-02-18

Record 2025 results featured 18% net sales growth and 27% higher net income, led by strong branded coconut water and international expansion. 2026 guidance calls for $680–$700 million in net sales, improved margins, and increased marketing investment, with private label growth ramping after Q1.

Q3 2025 Q3 2025 2025-10-29

Q3 net sales rose 37% year-over-year, led by 42% growth in branded coconut water and strong international gains. Full-year guidance was raised, but tariff and cost headwinds remain, with mitigation strategies in place. Cash position is robust, supporting growth and innovation.

Q2 2025 Q2 2025 2025-07-30

Net sales rose 17% to $169M in Q2 2025, led by 25% growth in coconut water and strong international gains. Gross margin declined to 36% due to higher costs and tariffs, but full-year sales guidance was raised to $565–$580M, with adjusted EBITDA expected at $86–$92M.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.